

B1  
cont

or different substituents from the group consisting of (C<sub>1</sub>-C<sub>4</sub>)-alkyl, hydroxyl and amino, and R<sup>2</sup> is hydrogen, or R<sup>1</sup> and R<sup>2</sup> are identical or different (C<sub>1</sub>-C<sub>4</sub>)-alkyl which can be substituted by one or more identical or different substituents from the group consisting of hydroxyl, (C<sub>1</sub>-C<sub>4</sub>)-alkoxy, (C<sub>1</sub>-C<sub>4</sub>)-alkyl-S(O)<sub>m</sub>-, R<sup>5</sup>R<sup>6</sup>N and aryl;

A1  
cont

in all its stereoisomeric forms and mixtures thereof in all ratios, or its physiologically tolerable salts.

0976593-02301  
TETRA-669260

4. (Amended) A compound of the formula I as claimed in [one or more of claims 1 to 3] claim 1, in which R<sup>1</sup> is (C<sub>3</sub>-C<sub>9</sub>)-cycloalkyl which can be substituted by one or more identical or different substituents from the group consisting of (C<sub>1</sub>-C<sub>4</sub>)-alkyl, hydroxyl and amino, and R<sup>2</sup> is hydrogen; in all its stereoisomeric forms and mixtures thereof in all ratios, or its physiologically tolerable salts.

5. (Amended) A compound of the formula I as claimed in claim 1 [ and/or 2], in which R<sup>1</sup>R<sup>2</sup>N- is an unsubstituted or substituted radical from the group consisting of piperidino, morpholino and thiomorpholino (and its S-oxide and S,S-dioxide) and piperazino; in all its stereoisomeric forms and mixtures thereof all ratios, or its physiologically tolerable salts.


6. (Amended) A compound of the formula I as claimed in [one or more of claims 1 to 5] claim 1, in which R<sup>3</sup> is substituted phenyl; in all its stereoisomeric forms and mixtures thereof in all ratios, or its physiologically tolerable salts.

## LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

7. (Amended) A compound of the formula I as claimed in [one or more of claims 1 to 6] claim 1, in which R<sup>4</sup> is (C<sub>3</sub>-C<sub>4</sub>)-alkyl; in all its stereoisomeric forms and mixtures thereof in all ratios, or its physiologically tolerable salts.

8. (Amended) A process for the preparation of compounds of the formula I as claimed in [one or more of claims 1 to 7] claim 1, which comprises activating a 4-hydroxypyrimidine of the formula IV and then reacting it with an amine of a formula VI,



where R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> have the meanings indicated in [claims 1 to 7] claim 1.

9. (Amended) A compound of the formula I as claimed in [one or more of claims 1 to 7] claim 1 and/or its physiologically tolerable salts for use as a pharmaceutical.

10. (Amended) A pharmaceutical preparation, which contains one or more compounds of the formula I as claimed in [one or more of claims 1 to 7] claim 1 and/or its/their physiologically tolerable salts and a pharmaceutically tolerable carrier.

LAW OFFICES

FINNEGAN, HENDERSON,  
 FARABOW, GARRETT,  
 & DUNNER, L.L.P.  
 1300 I STREET, N. W.  
 WASHINGTON, DC 20005  
 202-408-4000

B<sup>2</sup>  
cont

11. (Amended) A compound of the formula I as claimed in [one or more of claims 1 to 7] claim 1 and/or its physiologically tolerable salts for use as activators of soluble guanylate cyclase.

A<sup>1</sup>  
cont

12. (Amended) A compound of the formula I as claimed in [one or more of claims 1 to 7] claim 1 and/or its physiologically tolerable salts for use in the therapy or prophylaxis of cardiovascular disorders, endothelial dysfunction, diastolic dysfunction, atherosclerosis, high blood pressure, angina pectoris, thromboses, restenoses, myocardial infarct, strokes, cardiac insufficiency, pulmonary hypertension, erectile dysfunction, bronchial asthma, chronic renal insufficiency, diabetes or liver cirrhosis or for improving restricted learning capacity or memory power.

0076283060

Please add new claims 13-19.

A<sup>2</sup>

--13. A compound of the formula I as claimed in claim 5, in which R<sup>3</sup> is substituted phenyl; in all its stereoisomeric forms and mixtures thereof in all ratios, or its physiologically tolerable salts.

14. A compound of the formula I as claimed in claim 5, in which R<sup>4</sup> is (C<sub>3</sub>-C<sub>4</sub>)-alkyl; in all its stereoisomeric forms and mixtures thereof in all ratios, or its physiologically tolerable salts.

15. A process for the preparation of compounds of the formula I as claimed in claim 5, which comprises activating a 4-hydroxypyrimidine of the formula IV, and then reacting it with an amine of a formula VI,

where R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> have the meanings indicated in claim 1.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

16. A compound of the formula I as claimed in claim 5 and/or its physiologically tolerable salts for use as a pharmaceutical.

17. A pharmaceutical preparation, which contains one or more compounds of the formula I as claimed in claim 5 and/or its/their physiologically tolerable salts and a pharmaceutically tolerable carrier.

18. A compound of the formula I as claimed in claim 5 and/or its physiologically tolerable salts for use as activators of soluble-guanylate cyclase.

19. A compound of the formula I as claimed in claim 5 and/or its physiologically tolerable salts for use in the therapy or prophylaxis of cardiovascular disorders, endothelial dysfunction, diastolic dysfunction, atherosclerosis, high blood pressure, angina pectoris, thromboses, restenoses, myocardial infarct, strokes, cardiac insufficiency, pulmonary hypertension, erectile dysfunction, bronchial asthma, chronic renal-insufficiency, diabetes or liver cirrhosis or for improving restricted learning capacity or memory power.--

#### REMARKS

After entering this preliminary amendment, claims 1-19 are pending.

Claims 2-13 have been amended to eliminate their multiple dependency.

Additionally, claims 13-19 have been added. Claims 13-19 find support in originally-filed claims 1-13.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000